purposes, approximately 25% is used in food animals and 90% of that portion has been reported as being used in subtherapeutic concentrations for disease control and as growth promotants (Angulo; APHIS).
Antimicrobial agents have been added to feed and used extensively in swine production since their introduction in the early 1959s (Radostits, Leslie, and Fetrow). Swine performance is potentially improved by using subchemotherapeutic drugs to increase rate of' gain o r improve feed conversion (FDA). Because of the economic benefit to producers, antimicrobial dl-ugs are used in about 90%) of the starter feeds, 75% of the grower feeds. and over 50% of the finisher feeds (Cromwell) .
Growth promotant or subtherapeutic use of antimicrobials administered in animal feeds has been strongly criticized as a sel-ious public health threat, causing life-threatening infections that are resistant to antimicrobial therapy (Angulo; Witte) . This concern has developed around the following issues: (1) subtherapeutic use of antimicl-obials in animal feeds creates antimicrobial-resistant bacteria; (2) to humans would be reduced (National Re-search Council 1998b). However, in spite of these claims, there appears to be no clear-cut, definitive answer regarding whether subtherapeutic use causes adverse effects on human health (Mathews) . Nonetheless, it appears that human health officials are moving toward withdrawing antimicrobials that are used for growth promotants in animals if these drugs are also ~lsed for human therapeutics (Herrick) . Earlier studies on the economic impacts of bans on antimicrobial use in swine production conducted in the 1970s indicated an increase in the market price of pork and a 4-20% reduction in the quantity of pork supplied to the market (Gilliam et al.; USDA) . In 1985, the Animal Health Institute estimated that growth promotants save hog producers an estimated two billion dollars in annual production costs. Shifts in technology and changes in management systems would likely alter these results, which were obtained more than 15 years ago.
In two of the more recent economic studies dealing with the ban on subtherapeutic antimicrobials in swine production. a basic assumption was made that would appear to seriously flaw the results of these reports (Manchanda; Wade and Barkley) . Both of these studies assumed that there would be an increase in the demand for pork of 5% because of perceived improvements by consumers that pork produced under these bans would be more wholesome and less likely to contain antibiotic residues. This assumption seems to be unfounded because further decrease in the extremely low level of current antibiotic residue rates would be unlikely. The study by Wade and Barkley reported net econornic gains for both producers and consumers due to the proposed ban on antibiotics. If the demand for I While many of the antibiotics used in swine ( \ r e APHIS for a list of them) arc not approved for human use. they are still member.; of drug families that include human antibiotic\. Ractcria could develop reibtmcc in such a way that it was resi\tanl to all drugs within n drug family. Most bacteria that infect swinc do not infect hum~ins. But the t'car is that resistant hactcria could mutate and inl'ecl li~~mons or that the resislance co~~lci he tr;ln\fcrrcd to human bacteria through plasmid\ (In\titulc of Medicine).
antibiotic-free pork were genuine, market solutions' or labeling would be appropriate rather than an outright ban through regulation.
The most recently published economic evaluation (National Research Council 1998a) of the effects of a ban on subtherapeutic use of ~lntimicrobials in swine production also included some assumptions and methods that were questionable. This study assumed that there would be no change in consulnption with a concomitant increase in the market price of meat. N o elasticity measurements were included in this study that would make adjustments for changes in consumer demand due to price increases and provide for economic changes related to substitution effects among competing goods, such as beef or poultry.
The current climate of increased regulatory pressures by health officials and notable deficiencies or flaws in previously reported studies on the economic impact of restricted antimicrobial use policies indicate the need to obtain better quality information about this potential economic problem f a c i n~ the U.S. pork industry.
The objective of this study is to develop useful economic estimates of the impact of potential restricted-use policies fhr antimicrobial agents used in swine production as growth promotants. By using a model similar to that used by Wohlgenant, the economic impacts of banning antimicrobials in swine production are measured by the changes in producers' and consumers' surplus. plus in beef, pork, and poultry. Wohlgenant's model is modified in two dimensions: first, the two-commodity model is extended to a threecommodity model; second, the parameters corresponding to the shifts in demand curves are set equal to Lero and thus only effects of supply shifts are considered. Note that the model used by Wohlgenant assumes a parallel shift in supply. When the real shift in supply is not parallel, the impact might he overestimated or underestimated (Taylor) . Given that over 90% of swine producers use subtherapeutic antibiotics. a parallel shift appears to be a reasonable assumption. Explicitly, the modified model is ( I c )
where asterisks denote approximate relative changes (i.e., X* = d X I X ) : subscripts 1. 2 , and 3 denote beef, pork, and poultry. respectively; Q represents quantity of retail product: P is retail price; X is quantity of farm product, W is farm price: qIi is the elasticity of demand for the jth retail product with respect to price of the ith product; o, is the elasticity of substitution between the farm protiuct and marketing inputs in producing the jth product: S, is the farmer's cost share of theQth retail product; >: , is the elasticity of supply of thejth farm product; and 6, is the relative decrease in production cost for the jth farm product. Once the parameters in equation ( I ) are ~i v e n , the values of the variables with asterisks can be determined by solving the ecluations simultaneously. Using the total farin revenue and total consumer expenditures on each product and dropping the commodity subscripts to simplify notation. changes in producers' and consumers' surplus can be calculated as (2h) ACS = P Q P ' " ( ] t 0.5Q:"), where I P S denotes the change in producers' surplus and ACS denotes the change in consumers' surplus. The total farm revenue. WX, and total consumer expenditures. PQ, in each of the markets are predetermined.
All parameters necessary to apply the equations in (1) and (2), except the parameter representing the change in production costs, will be based on other researchers' results (e.g., Brester and Schroeder; Wohlgenant) . The production cost change parameter, k, is determined by simulations described as l'ollows.
Production Cost Changes Due to Banning Use of Growth Promotants
The production cost changes due to banning the use of antimicrobial growth promotants are ~neasured indirectly by the net benefits from using growth proniotants. Three key coniponents were identified as the most important for contributing potential economic advantages for growth promotant use at the producer level: (a) improved feed efficiency over drug cost, (b) reduced mortality rate, and (c) reduced sort loss at marketing. The net econonic benefit for growth prornotants in swine production is the sum of these components. The per animal net benefits are then used to calculate the net benefit at the industry level.
Econo~nic. Benqfir frorn Improvrcl F~~c.tl Eflic.ic,nc:v 0vc.r Dr~r,q Cosr
The stochastic relationship between the economic benefit per pig and the improvement in feed to gain conversions ( F I G ) in swine production is modeled as
where oc and p are the parameters to be estiniatcd and t. is a random variable with zero mean. Improvement in FIG is a random variable with a probability distribution to be determined.
Scientific literature was reviewed to determine the probability distribution o l the improvenlent in FIG and the parameters cx and p.
Journal of Agriculturul and Applied Econonzic~~, Dec.ernher 2002 This literature search provides the data shown in Table I . Reports were restricted to feeding trials using antimicrobial compounds that are presently available for use in swine; reports on those compounds under development or not yet approved for use by FDA in swine feed were excluded. Data from feeding trials limited to extremely brief periods of the production cycle, such as those associated with segregated early weaning programs and from the report based on producer surveys instead of actual feeding trials, were excluded from calculations.
Improvements in feed-to-gain ratio ( A linear regression is used to determine the parameters cx and p. Economic values derived from drug use during extremely brief periods of the production cycle or from therapeutic dose rates were excluded from the regression analysis. The regression based on the data in Table 1 shows the following estimated equation:
(4) economic benefit
This result is used to estimate the economic benefit per pig from the improvement in FIG.
Economic Benefit ,from Reduced Mortality Rate
Subtherapeutic use of antimicrobials affects mortality rates, especially on younger pigs, although these effects are not well documented.
Only two of the published reports in Table 1 provided data about differences in mortality rates associated with the use of antimicrobial agents. Walter, Holck, and Wolff evaluated therapeutic levels of tiamulin and chlortetracycline fed from 1 1 weeks of age for a period of 16 weeks to more than 1,000 modern crossbred lean genotype barrows in a commercial swine production system. Treatments were divided among continuous delivery of medication in feed, "pulse" delivery of medication for 7 days administered every 2 or 3 weeks, and a nonmedicated control group. Mortality rates for pigs in these groups were 0.55, 1.92, and 5.2296, respectively, with both medication groups having significantly less mortality than controls. Gourley evaluated low-level continuous and high-level "pulse" (I week out of 4) medication regiments for delivering chlortetracycline in feed to 576 growerlfinisher pigs from a lean genotype, high health swine herd. The third treatment was a nonmedicated control group. The mortality rates for the three treatment groups were 2.60, 2.08, and 3.1 3%, respectively. Although both medicated groups had lower mortality than the nonmedicated group, none of the three mortality levels were significantly different from the others. The average mortality benefit from the two published reports is 1.43%, but the nonmedicated control group in the Walter, Holck, and Wolff study had death losses above those normally expected in commercial herds. We therefore model the mortality benefit associated with growth promotants as a symmetric triangular distribution with minimum 0, most likely 0.75, and maximum 1.5%. The market price used for hogs is $45.00 per cwt. This price is based on an approximate 10-year average market hog price (Walter, Holck, and Wolff) . The market price of hogs is used indirectly to establish the value of 40 Ib. feeder pigs needed to calculate benefits associated with reduced mortality rates. Using current feeder pig pricing schedules as a guideline (Iowa Department of Agricultural Market News), we also assume that heavier feeder pigs are worth $0.45 per pound for additional weight over 40 lbs. Weights of pigs h Data were limited to only a portion of the grower/finisher phase. Economic data that were used to develop ecc~nomic association with corresponding improvements in F : G ratio.
,J Data were developed from a producer survey and not based upon feeding trials. Ecollornic data thar were not used because antimicrobials were fed at therapeutic rates. When the weights of ~narket hogs fall outside of the packel--specitied weight range. pricing discounts are applied, especially for lightweight hogs, based on price schedules o r "grid" pricing. The term "sort loss" has been used by the swine industry to iiescribe the dotlar loss related to these market hogs. which receive price discounts. Growth prornotants irnprove the i~niforrnity of average daily gain and therefore reduce the ending weight variability and associated sort loss for market hogs (Gourley: Gourley and Wolff; Tillman). The size of the sort loss benefit would vary uccording t o the type of feeding man;igement. Production systems using targeted days o n feed would achieve potentially greater benefits related LO reclucrd sort loss conlpared with targeted marketing weight management systems because the tirne schedule for a targctcd days system ~v o~r l d typically provide less opportunity for delayed niarketing to allow additional gain for lighter weight pigs. A report by Tillrnan provided data on avel-age ending weight and standard deviations for the effect of a growth promotant on reducing sort loss in rnarket hogs compared with a control group based on a targeted days on feed production system. The normal distribution function was used t o determine c u m u l a t i v e proportions within each group. Then the cumulative proportions were used as inputs for calculating differences in distributions between these two groups. Sort losses at slaughter were based on grid pricing discour~ts announced by Farmland for underweight hogs (Table 2 ). These data provide an overall mean value of $1.39 with standard deviation of $0.15 per hog benefit for growth promotants in reducing sort loss for targeted days production systerns. To avoid overestimating thc benefit from reduction i n sort loss, it is assumed that this benefit would be only one third as much, i.e., mean $0.46 with standard deviation $0.05 Ibr hogs procluced under targeted weight production systems because of increased opportunity to allow longer feeding periods to achieve desired As outlined before, the total net economic benefits l'rom using growth promotants are from three random sources, i.e.. normally distributed impro\fenient in FIG, triangularly distributed reduced mortality I-ate, and normally distributed reduced sort loss at marketing. To estimate the total economic benetits, we need to convert the scale from producer level to industry level. The number of market barrows and gilts slaughtered per year is extrapolated from annual USDA livestock slaughter summary reports for years 1994-2000. These summaries report figures ranging from 86.5 to 9 6 million head for years I996 and 1999. respectively. Based on these data, annu211 production of 100 million market burrows and gilts is assumed for the simulation.
The proportion of growerfiinisher pigs receiving antimicl-obials as growth promotants and the proportion of growerttinisher pigs managed as all-inlall-out are based o n population estimates from the Swine '95 project (Animal and Plant Health and Inspection Service; Centers for Epidcmiology and Animal Health) (see Table 3 ). We project that XSYr of growerlfinisher pigs would receive growth promotants in feed and that 55% of hogs w o~~l d be raised in an all-intall-out growerltinisher system.
Once the probability distributions of the three sources of economic benefits at the industry level are given, the total net economic benefits are estimated by s~~t n m i n g the benefits of each of the three co~nponents. The expected net benefit c o~~l d have been well approximated with analytical methods by assuming normality. The Monte Carlo method, however. accommodates nonnormal distt-ibutions and provides a convenient way of calculating the uncertainty of the estimate.
Kesults
Based on a 5.000 iteration simulation, the total estimated net benetit l'or subtherapeutic use of antibiotics in swine production was calculated as $2.76 i-$0.56 per hog as determined by the previously described components ( Figure  2) . Although a wide spread in the value of this benefit was possible, the majority of values most likely to occur would range fi-om $2.37 to $3. I I per hog. The average benefit of $2.76 pel-hog was used to calculate the proportional change in production costs for the swine industry and the I-esulting impact on economic values related to changes in supply and demand of pork in the United States if the use of subtherapeutic antibiotics in feed were banned. If the resulting change in cost oS pork production is lower or higher than assumed, all nurnbers change proportionately. The calculated average incl-cased cost of production 01' $2.76 per hog due to loss of the net benefits ;issociated with growth promotants was considered to be the best estimate for figuring the cost change listed in Table 4 . Two different sets of supply elasticities are considered because they are key parameters and there is little data on what values to use.
Given all parameters and data in Table 1 . the variables with asterisks in equation ( I ) , i.e., the retail products, retail prices, farm products, and farm prices for the three commodities, are obtained by solving the simi11-tancous ecluations ( 1 ) . Substituting the solution for ( I ) into (2). we obtained changes in producers' and consumers' s~lrplus. By setting specific parameters equal to zero, the changes in producers' and consumers' surplus obtained are the ones due to banning subtherapeutic antibiotics in swine only or both swine and poultry production.
The total annual loss in the short run would be $242.5 million (the sum of the tirst row in Table 5 ) . Table 5 shows that, in the short run, the estimated loss borne by swine producers would be $153.5 million. In the long run, the swine producer surplus loss would be $99.2 million if the elasticity for each of the commodities is 0.5, ancl only $62.4 nill lion with a more elastic supply. The results from the two sets of long-run elasticities show that a change in the elasticity does not change the total i n - and therefore the net effect o f a ban might b e a n increase in mortality. T h e r e is also a positive probability o f s o m e unforeseen catastrophic event. But Shogren (p. 314) argues that the probabilities of such events are often overestimated.
Conclusion
A ban o n the use of antimicrobial agents as growth proniotantsfor swine would b e costly, totaling $242.5 million annuiilly, with swine producers bearing $153.5 million o f the cost in the short run. In the long run, the loss borne by consumers would likely b e larger than the loss borne by producers. Based o n a 30-year planning horizon and a 4 % discount rate, the net present value of these increased costs would b e $3.2 billion.
T h e ban considered here w a s a complete ban o n all microbial agents. A ban that included only the f e w antibiotics that a r e also used for h u m a n s might have little effect o n the swine industry. Also, producers might b e able t o change management practices in unexpected w a y s t o compensate f o r the loss o f antimicrobials. Thus, the actual losses from a ban might b e smaller than the losses estimated here. It should b e noted that w i d e ranges o f published elasticity estimates w e r e available. T h e elasticity estimates determined whether producers o r consumers incurred the cost o f the ban. Because pork production uses t e w resources that are specialized and fixed in the long run (although this m a y c h a n g e with increasing regulation). its supply c u r v e is likely elastic in the long run and s o consumers would incur m o r e o f the long-run cost of the ban.
T h e estimates o f the total cost oP banning subtherapeutic antimicrobial use in swine were roughly half o f that estimated b y the Cornrnittee o n D r u g Use in Food Animals (National Research Council I99Xa). T h e key differe n c e w a s that they assumed that marketing cost would increase proportionately to any change i n production cost, while this model held marketing costs constant.
